The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Lenka Špinarová et al.|Nature Medicine|2022Cited by 889
The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF StudyGeorge Markousis‐Mavrogenis, Peter van der Meer, Jasper Tromp et al.|European Journal of Heart Failure|2019Cited by 281
Age dependent associations of risk factors with heart failure: pooled population based cohort studyJasper Tromp, Jennifer E. Ho|BMJ|2021Cited by 227
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trialJan Biegus, Piotr Ponikowski, Adriaan A. Voors et al.|European Heart Journal|2022Cited by 213
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail Kosiborod, Adriaan A. Voors, Christiane E. Angermann et al.|Circulation|2022Cited by 142